trial · primary record
CT-179
Recurrent Glioblastoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2028-09 |
| Primary endpoint | Determine Maximum Tolerated Dose (MTD) in TA1 in patients with rGBM |
| Registry ID | NCT07739017 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:09.772Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07739017
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.